FinTechFunding

Avecho Biotechnology: Records positive results from Phase IIa osteoarthritis study

Avecho Biotechnology Records positive results from Phase IIa osteoarthritis study

  • Avecho Biotechnology (AVE) sees positive results from its Phase IIa Study of its CBD formulation on patients with osteoarthritis (OA)
  • The study investigated the effects of a topical CBD gel on OA of the hand with 15 patients recruited to apply Avecho’s TPM formulation daily to the affected joints
  • The primary aim of the study was to measure the change in daily hand pain while the secondary aim included improving hand functionality
  • Over the four weeks, daily improvements were encountered in hand pain, hand functionality, grip strength, stiffness and anxiety
  • Avecho is up 7.69 per cent on the market with shares trading at 1.4 cents
Previous article
Twenty Seven Co: Completes auger drilling program at Yarbu, WA
Next article
Carnarvon Energy: Raises $70m for Dorado field development
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...
FinTech

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...
FinTech

UK Banks Strengthen Cybersecurity with Anthropics Mythos Model

New collaboration enhances banks' defense against cyber threats.Highlights: UK banks to access Anthropics Mythos model in the upcoming...
FinTech

UK Banks to Gain Access to Anthropic Cybersecurity Model Next Week

New collaboration enhances cybersecurity for UK banking institutions.Highlights: UK banks set to access Anthropic's cybersecurity model soon.Collaboration aims...